EBR Systems (EBR: $1.12) is developing the world's first wireless pacing system for the left ventricle of the heart. The company recently announced positive clinical results from its pivotal US study which opens the path for FDA registration of the device.

The results from EBR Systems'(EBR: $0.905) pivotal study will be presented at the Heart Rhythm 2023 meeting this weekend. EBR is holding a webinar this Monday morning to discuss the results.

EBR Systems (EBR: $0.60) is a relatively new biotech on the ASX, having listed in November 2021 at $1.08 per share, raising $110 million. It is developing the world's first and only wireless electronic heart pacing system for the left ventricular, called WiSE. It is being trialled with commercially available right ventricle pacers (both with leads and wireless) to offer a novel cardiac resynchronisation therapy (CRT).

Background
EBR Systems is a single product medical device company developing a wireless electrode designed to stimulate the left ventricle (LV) for biventricular cardiac re-synchronisation therapy (CRT). CRT is a mainstay of treatment for late-stage heart failure. The WiSE (Wireless Stimulation Endocardially) electrode represents a step change in CRT for the key reason that it is already the first ever device to achieve a CE mark for implantation to the endocardium (inside) of the left ventricle.